The main trial compared Mounjaro with higher dose semaglutide, not standard Ozempic dosing. Keep this in mind when reading the results.
Mounjaro and Ozempic are once-weekly injections for diabetes, both widely discussed for weight loss. Mounjaro has an obesity indication in India, but Ozempic’s weight-loss use here is off-label. This guide sets out what the evidence actually shows.
Quick Answer
- In the head-to-head SURMOUNT-5 trial behind most claims, tirzepatide produced greater weight loss, but the semaglutide dose used was the higher obesity dose sold as Wegovy, not standard Ozempic dosing.
- Semaglutide has established cardiovascular and kidney evidence in type 2 diabetes with chronic kidney disease. Tirzepatide now has its own cardiovascular outcome trial too, published December 2025.
- Branded Ozempic costs about Rs 5,660 to Rs 9,100 a month in India. Branded Mounjaro costs about Rs 13,100 to Rs 27,500. Generic semaglutide is available from about Rs 1,290. There is no generic tirzepatide yet.
- Neither is automatically “better.” The right choice depends on your goals, your other health conditions, and what you can afford, decided with your doctor.
Mounjaro vs Ozempic: How Are They Different?
Ozempic is semaglutide, a GLP-1 receptor agonist. It raises insulin after meals, slows digestion, and reduces appetite. Novo Nordisk makes it, approved for diabetes in 2025.
Mounjaro is tirzepatide, activating both GLP-1 and GIP receptors, which may contribute to its generally larger trial effects. Eli Lilly makes it, approved in India for diabetes and obesity, so weight-loss use is on-label.
Weight Loss: What the Evidence Actually Shows
The main head-to-head trial is SURMOUNT-5, published in NEJM and funded by Eli Lilly, tirzepatide’s maker, enrolling 751 adults with obesity but no diabetes for 72 weeks at each drug’s top tolerated dose. Tirzepatide produced 20.2 percent weight loss versus 13.7 percent with semaglutide, about 22.8 kg against 15.0 kg.
The detail that changes how to read this: the semaglutide dose was 1.7 to 2.4 mg, the Wegovy range, not the lower doses typically used for Ozempic. SURMOUNT-5 is genuinely tirzepatide versus obesity-dose semaglutide, not a like-for-like test against standard Ozempic. On side effects, more people on semaglutide stopped due to GI problems, 5.6 percent versus 2.7 percent on tirzepatide.
A separate 2021 trial, SURPASS-2, found a similar pattern in type 2 diabetes, with tirzepatide’s highest dose giving more weight loss than semaglutide’s standard dose.
Blood Sugar and HbA1c
In SURPASS-2, tirzepatide’s highest dose lowered HbA1c about 2.4 points against 1.9 for semaglutide, a modest gap. Semaglutide’s edge lies in years of dedicated outcome data. The HbA1c normal range chart explains what these numbers mean for your own results.
Heart and Kidney Evidence: What We Know About Each Drug
Semaglutide has cardiovascular and kidney evidence from the FLOW trial, specifically in type 2 diabetes with chronic kidney disease, not a blanket claim for every user.
Tirzepatide’s cardiovascular evidence has also grown. SURPASS-CVOT included 13,299 people with type 2 diabetes and heart disease and was published in December 2025. The primary cardiovascular outcome occurred in 12.2 percent of the tirzepatide group and 13.1 percent of the dulaglutide group, meeting the trial’s noninferiority criterion. The trial did not compare tirzepatide directly with semaglutide, so it does not show that one provides greater cardiovascular benefit than the other.
Evidence at a Glance
Price in India
After Novo Nordisk’s April 2026 cut, Ozempic costs Rs 5,660 to 9,100 a month, Mounjaro Rs 13,100 to 27,500, two to three times more. Generics launched near Rs 1,290 after the March 2026 patent expiry. No generic tirzepatide exists yet. Exact MRPs by pack, sourced from Reuters and Business Standard reporting dated September 2026, are detailed in our guides to the Mounjaro price and the Ozempic price in India.
Approved semaglutide products share the active ingredient, but brand, device, and strength differ, so use what your doctor prescribes. Insurance coverage depends on policy, and weight-loss use is often excluded.
Reported Side Effects, Not a Direct Comparison
Both drugs share stomach-related side effects, worst in the first weeks and after dose increases. Figures are reported rates from separate trials, a general pattern, not a direct comparison.
| Side Effect | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Nausea | Common, roughly 16 to 20 in 100 | Common, roughly 12 to 18 in 100 |
| Diarrhoea | Common, roughly 8 to 9 in 100 | Common, roughly 12 to 17 in 100 |
| Vomiting | Common, roughly 5 to 9 in 100 | Common, roughly 5 in 100 |
| Constipation | Common | Common |
These percentages come from different clinical trials and doses, and should not be used to decide which medicine causes fewer side effects.
Rarer risks apply to both: pancreatitis, gallbladder problems, low blood sugar with insulin. Both carry a boxed warning about thyroid C-cell tumours in animal studies, unsuitable with a family history of medullary thyroid cancer or MEN2.
If You Use Oral Birth Control (Tirzepatide)
Tirzepatide’s label states it can reduce absorption of oral contraceptives by delaying stomach emptying. Use a non-oral or barrier method for 4 weeks after starting and after each dose increase.
If You Have Diabetic Eye Disease (Semaglutide)
Tell your doctor about any history of diabetic retinopathy before starting semaglutide. A rapid blood sugar drop can temporarily worsen it in some patients.
Pregnancy and Breastfeeding
Neither drug should be used during pregnancy. Semaglutide’s label specifically advises stopping at least two months before a planned pregnancy because it clears slowly. Tirzepatide’s label has its own pregnancy and contraception guidance, noted below. If breastfeeding, ask your doctor before starting either medicine.
Mounjaro, Ozempic, or Wegovy?
Ozempic and Wegovy share the molecule semaglutide, Ozempic the diabetes dose, Wegovy the higher weight dose. Mounjaro is a different molecule, tirzepatide, approved for both. For weight management specifically, the most relevant head-to-head evidence compares tirzepatide with obesity-dose semaglutide, sold as Wegovy, not with standard Ozempic.
What the Evidence Favours, by Goal
This is a starting point for a conversation, not a prescription. Age, weight, HbA1c, kidney function, and cost all factor in.
The Bigger Picture
Both medicines work alongside diet and activity. Obesity treatment is often long term, and stopping frequently leads to weight regain. If your blood sugar is only mildly raised, you may not need either drug yet. Our guides on reversing prediabetes, the normal blood sugar range, and early signs in young Indians are a good place to check where you stand first.
When to See a Doctor
Get same-day help for severe stomach pain spreading to the back with vomiting, a possible sign of pancreatitis, or for shaking, sweating, or confusion suggesting low blood sugar. Talk to your doctor first if thyroid cancer runs in your family, gallbladder disease, or pregnancy is possible.
Key Takeaways
- The famous head-to-head trial used the higher Wegovy dose of semaglutide, not standard Ozempic dosing.
- Both medicines now have cardiovascular outcome evidence, but from different populations and comparators, not a direct head-to-head.
- Ozempic and generic semaglutide cost far less than Mounjaro in India, with no tirzepatide generic yet.
- This is a conversation to have with your doctor, not a winner to pick from a table.
Frequently Asked Questions
Is tirzepatide the same as semaglutide?
No. Semaglutide activates one gut hormone receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. In head-to-head trials, tirzepatide has generally produced somewhat greater weight loss and blood sugar reduction, though not every dose combination has been directly compared.
Can I use Mounjaro or Ozempic for weight loss without diabetes?
Mounjaro is approved in India for obesity as well as diabetes. Ozempic is approved only for diabetes, and using it for weight is an off-label decision made with a doctor. Wegovy is the semaglutide brand approved specifically for weight management.
Is generic semaglutide as good as branded Ozempic?
Approved generics contain semaglutide as the active ingredient, cleared by India’s regulator. The maker, device, strength, and sometimes the approved indication can differ, so use the specific product and dose your doctor prescribes.
Which is cheaper in India, Mounjaro or Ozempic?
Ozempic. Branded Ozempic runs about Rs 5,660 to Rs 9,100 a month, while branded Mounjaro runs about Rs 13,100 to Rs 27,500. Generic semaglutide is cheaper still, from about Rs 1,290 a month.
Can you take Mounjaro and Ozempic together?
No, this is not a standard approach. Both act on overlapping hormone pathways, and combining them is not how either is studied or prescribed. Switching between them, rather than combining, is sometimes done under medical supervision.
Does Mounjaro now have heart-protection evidence like Ozempic?
Yes, a newer trial. SURPASS-CVOT, published December 2025, found the primary cardiovascular outcome in 12.2 percent of the tirzepatide group against 13.1 percent with dulaglutide, meeting the trial’s noninferiority criterion, in people with type 2 diabetes and existing heart disease. It was not compared directly with semaglutide, so it does not show one drug is superior to the other for heart protection.
Will I regain weight if I stop either drug?
Often, yes. Follow-up studies of both drugs show many people regain a large part of the lost weight within a year of stopping. Doctors increasingly treat obesity as a long-term condition, so any plan to stop should be made with your doctor.
Do I need a prescription for either medicine in India?
Yes. Both are prescription-only. The dose is raised gradually and needs monitoring for side effects, so neither should be bought or started without a doctor’s supervision.
References and Sources
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. SURMOUNT-5.
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide, including discontinuation rates. 2025.
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025, volume 393, pages 2409 to 2420. SURPASS-CVOT.
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. SURPASS-2.
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. FLOW trial.
- Reuters. Novo Nordisk launches Ozempic in India, December 2025, and subsequent India pricing reports, 2026.
- Business Standard. Novo Nordisk cuts Ozempic and Wegovy prices in India. April 2026.
Written by
Iraphan Khan, BSN, RN, D.Pharm, Public Health Researcher
Founder of RealMedVision, writing patient-focused health content based on clinical guidelines and peer-reviewed research. This article is not a substitute for consultation with a licensed physician.
Medically reviewed by
Dr Praveen Verma, MBBS, MD (Pathology), Pathologist and Clinical Laboratory Specialist
Dr Himanshu Morya, MBBS, Medical Educator
This article is for information and education only, and is not a substitute for professional medical advice. Mounjaro and Ozempic are prescription medicines. Prices are approximate figures for September 2026 and change by pharmacy, city, and dose. Do not start, stop, or change any treatment without talking to a qualified healthcare professional who knows your full history.